ClinicalTrials.gg
Approved for marketingNCT04056481Updated May 20, 2024

Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria

An expanded access record providing Givosiran in Acute Hepatic Porphyria, sponsored by Alnylam Pharmaceuticals. Approved for marketing. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-05-20.

Sponsored by Alnylam Pharmaceuticals · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Treatment IND/protocol
Ages
12 Years and older
Sex
All
01

Study summary

The purpose of this study is to provide expanded access of givosiran to patients with Acute Hepatic Porphyria (AHP).

Read the detailed description

Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact the study research staff using the Contacts provided. For general information, see the link provided in More Information.

02

Conditions studied

  • Acute Hepatic Porphyria

Keywords

  • Acute Hepatic Porphyria (AHP)
  • Acute Intermittent Porphyria (AIP)
  • Porphyria
  • Acute Intermittent
  • Acute Porphyria
  • Hereditary Coproporphyria (HCP)
  • Variegate Porphyria (VP)
  • ALA Dehydratase Deficient Porphyria (ADP)
  • Givosiran
  • Expanded Access
  • EAP
03

In context

Porphyria, Acute Intermittent

21 studies on the registry are indexed under Porphyria, Acute Intermittent; 3 are open to participants now.

Browse Porphyria, Acute Intermittent studies →

Lead sponsor

Alnylam Pharmaceuticals is the lead sponsor of 84 studies on the registry; 18 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 15 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with Acute Hepatic Porphyria (Acute Intermittent Porphyria, Hereditary Coproporhyria, Variegate Porphyria, ALA dehydratase deficient porphyria)
  • Have adequate venous access for program sample collections as judged by the Investigator for study sample collections

Exclusion criteria

Exclusion Criteria:

  • Previously or currently participating in a givosiran clinical trial
  • Has any of the following laboratory parameter assessments at Screening:

    1. (ALT) >2×
    2. Total >1.5×ULN. Patients with elevated total bilirubin that is secondary to documented Gilbert's syndrome are eligible if the total bilirubin is \<2×ULN
    3. Estimated (eGFR) \<15 mL/min/1.73 m2
  • On an active liver transplantation waiting list
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Access details

Study type
Expanded access
Access type
Treatment IND/protocol

Available treatment

  • givosiran (ALN-AS1) administered as a subcutaneous (SC) injection

    Also known as: ALN-AS1

06

Where to request access

No study locations are listed for this record.

07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT04056481
Responsible party
Sponsor
First posted
Aug 14, 2019
Last update
May 20, 2024

Study contacts

Medical Director
study director · Alnylam Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion